Zevalin, Bexxar Off-Label Coverage Decision Affirms Status Quo
Executive Summary
Medicare contractors will retain the discretion to determine when to cover Biogen Idec's Zevalin and GlaxoSmithKline's Bexxar for off-label use in non-Hodgkin's lymphoma under a proposed coverage determination issued by the Centers for Medicare & Medicaid Services May 4
You may also be interested in...
CAR-T Reimbursement Threatened By Medicare Coverage Analysis, Manufacturers Say
Novartis, Gilead/Kite and Celgene protest the US Centers for Medicare and Medicaid Services’ decision to launch a Medicare coverage analysis for CAR-T drugs because it might lead to coverage restrictions.
A Closer Look: Decision For No Medicare NCD On ESAs In Renal Disease Would Be The Exception
Many industry watchers were surprised when the Centers for Medicare and Medicaid Services conducted an extensive evidence analysis of ESAs, only to propose on March 16 no policy change. Indeed, the outcome, if made final, would be quite unusual, a look at numerous coverage analyses shows.
A Closer Look: Decision For No Medicare NCD On ESAs In Renal Disease Would Be The Exception
Many industry watchers were surprised when the Centers for Medicare and Medicaid Services conducted an extensive evidence analysis of ESAs, only to propose on March 16 no policy change. Indeed, the outcome, if made final, would be quite unusual, a look at numerous coverage analyses shows.